CYP2C9
| is a | gene |
| is | mentioned by |
| Full name | cytochrome P450, family 2, subfamily C, polypeptide 9 |
| EntrezGene | 1559 |
| PheGenI | 1559 |
| VariationViewer | 1559 |
| dbSNP | 1559 |
| SADR | 1559 |
| HugeNav | 1559 |
| CYPANC | cyp2c9 |
| wikipedia | CYP2C9 |
| CYP2C9 | |
| gopubmed | CYP2C9 |
| EVS | CYP2C9 |
| HEFalMp | CYP2C9 |
| 23andMe | CYP2C9 |
| UniProt | P11712 |
| Ensembl | ENSG00000138109 |
| OMIM | 601130 |
| EVS | CYP2C9 |
| # SNPs | 29 |
| Max Magnitude | Chromosome position | Summary | |
|---|---|---|---|
| Rs10509680 | 3 | 96,734,339 | |
| Rs1057909 | 4 | 96,741,051 | |
| Rs1057910 | 3.5 | 96,741,053 | Warfarin (Coumadin®) |
| Rs1057911 | 3 | 96,748,737 | |
| Rs12572351 | 0 | 96,703,220 | |
| Rs17847042 | 0 | 96,741,053 | |
| Rs1799853 | 2.1 | 96,702,047 | Warfarin (Coumadin®) |
| Rs1934967 | 96,741,426 | ||
| Rs1934968 | 0 | 96,741,817 | |
| Rs2017319 | 0 | 96,748,635 | |
| Rs2256871 | 0 | 96,708,974 | |
| Rs28371685 | 2.5 | 96,740,981 | Warfarin (Coumadin®) |
| Rs28371686 | 2.5 | 96,741,058 | Warfarin (Coumadin®) |
| Rs4086116 | 0 | 96,707,202 | |
| Rs4917639 | 96,725,535 | ||
| Rs56165452 | 0 | 96,741,054 | |
| Rs67807361 | 0 | 96,698,494 | |
| Rs7089580 | 0 | 96,705,223 | |
| Rs72558187 | 0 | 96,701,715 | |
| Rs72558188 | 4 | 96,701,970 | |
| Rs72558189 | 2.5 | 96,701,991 | Warfarin (Coumadin®) |
| Rs72558190 | 0 | 96,707,539 | |
| Rs72558191 | 0 | 96,707,676 | |
| Rs7900194 | 0 | 96,702,066 | |
| Rs9332127 | 0 | 96,707,471 | |
| Rs9332130 | 0 | 96,709,037 | |
| Rs9332131 | 2.5 | 96,709,039 | Warfarin (Coumadin®) |
| Rs9332146 | 0 | 96,722,244 | |
| Rs9332239 | 0 | 96,748,777 |
SNPs in CYP2C9 include:
- rs1057910; two variants encode the CYP2C9*1 and CYP2C9*3 alleles
- rs1799853, versions of which encode CYP2C9*2 alleles
A recent FDA action stipulates that the possibility of genetic testing for SNPs in the CYP2C9 gene be included on the label for the medicine known as warfarin (trade name Coumadin).
Plavix, the trade name for clopidogrel, is a drug commonly prescribed to reduce the chance of a type of heart disease (acute coronary syndrome), and it inhibits CYP2C9 at high enough doses. This may therefore interfere with the metabolism of drugs processed by CYP2C9, and individuals with CYP2C9 SNP variants that encode lower metabolizers to begin with would presumably be at greater risk for such side-effects when taking Plavix at the same time as drugs metabolized by CYP2C9.
A more detailed list of CYP2C9 SNPs includes:
In one of the largest "negative" studies reported to date, three independent studies totaling over 52,000 individuals found no association between CYP2C9 polymorphisms (specifically, the *2 and *3 alleles) and risk of subclinical atherosclerosis, ischemic vascular disease or death after ischemic heart disease.[PMID 19652664]
